Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy-Reference-Cited by-同舟云学术

Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy

Published:2014-03-13 Issue:6 Volume:16 Page:815-822
ISSN:1523-5866
Container-title:Neuro-Oncology
language:en
Short-container-title:

Author:

Piccioni David E.,Selfridge Julia,Mody Reema R.,Chowdhury Reshmi,Li Sichen,Lalezari Shadi,Wawrzynski James,Quan Jennifer,Zurayk Mira,Chou Arthur P.,Sanchez Desiree E.,Liau Linda M.,Ellingson Benjamin M.,Pope Whitney B.,Nghiemphu Phioanh L.,Green Richard M.,Wang He-jing,Yong William H.,Elashoff Robert,Cloughesy Timothy F.,Lai Albert

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Clinical Neurology,Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/16/6/815/16664848/nou028.pdf

Reference24 articles.

1. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;NEng J Med,2005

2. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme;Cohen;Oncologist,2009

3. Bevacizumab as first-line therapy for glioblastoma;Piccioni;Future Oncol,2012

4. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States;Grossman;Clin Cancer Res,2010

5. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme;Lai;J Clin Oncol,2011

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map;BMC Cancer;2023-06-14

2. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma;Journal of Neuro-Oncology;2021-10-25

3. Strategies to better treat glioblastoma: antiangiogenic agents and endothelial cell targeting agents;Future Medicinal Chemistry;2021-02

4. Clinical Outcome of Cytoreductive Surgery Prior to Bevacizumab for Patients with Recurrent Glioblastoma: A Single-center Retrospective Analysis;Neurologia medico-chirurgica;2021

5. Therapeutic approaches to overcome temozolomide resistance in glioblastoma;Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies;2021